BSE SENSEX
48,832.03+28.33(+0.06%)Nifty 50
14,617.85+36.35(+0.25%)Dow
34,200.67+164.67(+0.48%)
Vertex Pharmaceuticals Incorporated (VRTX)
| Previous close | 221.10 |
| Open | 222.34 |
| Bid | 219.40 x 1200 |
| Ask | 221.99 x 900 |
| Day's range | 219.24 - 222.77 |
| 52-week range | 202.57 - 306.08 |
| Volume | 1,917,605 |
| Avg. volume | 2,069,529 |
| Market cap | 56.783B |
| Beta (5Y monthly) | 0.68 |
| PE ratio (TTM) | 21.32 |
| EPS (TTM) | 10.29 |
| Earnings date | 27-Apr-2021 - 03-May-2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 285.42 |
- Zacks
Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know
Vertex Pharmaceuticals (VRTX) closed at $217.13 in the latest trading session, marking a +0.55% move from the prior day.
- Zacks
Biotech Stock Roundup: BLUE/BMY's CAR T Therapy Nod, KLDO's COVID-19 Study News & More
The biotech sector gains prominence with new product approvals from bluebird (BLUE)/Bristol Myers Squibb (BMY) and other coronavirus updates.
- Business Wire
Vertex Receives CHMP Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With Cystic Fibrosis With At Least One F508del Mutation
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the label extension of KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in a combination with ivacaftor 150 mg tablets for the treatment of cystic fibrosis (CF) in all patients ages 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, the most common CF-causing mutation worldwide. If the European Commission follows the recommendation, the majority of people with CF in Europe will be eligible for the medicine.
